1. A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment
- Author
-
Luciano Pirone, Annarita Del Gatto, Sonia Di Gaetano, Michele Saviano, Domenica Capasso, Laura Zaccaro, and Emilia Pedone
- Subjects
0301 basic medicine ,integrin ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Integrin ,ACE2 ,Computational biology ,spike protein ,medicine.disease_cause ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Ganglioside binding ,Pandemic ,medicine ,Molecular Biosciences ,lcsh:QH301-705.5 ,Molecular Biology ,Integrin binding ,Galectin ,Coronavirus ,Multi targeting ,galectin ,ganglioside ,biology ,multi targets against SARS-Cov2 ,030104 developmental biology ,lcsh:Biology (General) ,030220 oncology & carcinogenesis ,Perspective ,biology.protein - Abstract
The public health has declared an international state of emergency due to the spread of a new coronavirus (SARS-CoV-2) representing a real pandemic threat so that to find potential therapeutic agents is a dire need. To this aim, the SARS-CoV-2 spike (S) glycoprotein represents a crucial target for vaccines, therapeutic antibodies, and diagnostics. Since virus binding to ACE-2 alone could not be sufficient to justify such severe infection, in order to facilitate medical countermeasure development and to search for new targets, two further regions of S protein have been taken into consideration here. One is represented by the recently identified ganglioside binding site, exactly localized in our study in the galectin-like domain, and the other one by the putative integrin binding sites contained in the RBD. We propose that a cooperating therapy using inhibitors against multiple targets altogether i.e., ACE2, integrins and sugars could be definitely more effective.
- Published
- 2020
- Full Text
- View/download PDF